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Angiogenesis and lymphangiogenesisBone morphogenetic proteins (BMP) are members of the transforming growth factor b superfamily (TGF-
b). BMPs are involved in tumourigenesis and disease progression of certain malignancies. To date, the role
played by BMPs in gastric cancer (GC) remains largely unknown. In the present study, we systematically
analysed the expression and clinical significance of BMP and BMP receptors (BMPR) in TCGA gastric can-
cer database and GEO database and explored the possible mechanism of action. BMP5 is reduced in gas-
tric cancer tissues, while ACVRL1, ACVR1, TGFBR1, and BMPR2 were significantly increased in the gastric
tumours. BMP3, ACVR1, TGFBR1, BMPR1B (also known as ALK6), TGFBR2 and BMPR2 were significantly
associated with poorer overall survival of GC patients. A negative correlation was seen between BMP/
BMPR and proliferation markers which was supported by their correlation with the cell cycle promoters
and inhibitors. More interestingly, further analyses showed that BMPs and their receptors are positively
correlated with matrix metalloproteinases (MMPs), epithelial mesenchymal transition (EMT) markers
and stemness in GC. Furthermore, positive correlations were also frequently seen between BMP receptors
and markers/regulators of angiogenesis and lymphangiogenesis in the gastric tumours. Taken together,
these findings suggest that BMPs play dual roles in GC. They may inhibit proliferation of GC cells. On
the other hand, they can also promote disease progression through a promotion of invasion, EMT and
stemness. The elevated expression of BMP receptors in GC were also highly associated with tumour
associated angiogenesis and lymphangiogenesis which facilitate tumour growth, expansion and spread.
 2020 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gastric cancer (GC) is one of the most common gastrointestinal
malignancies and the second leading cause of cancer-related death
worldwide [1]. To date, patients with GC have poor prognosis, with
a 5-year survival rate of between 25 and 30% [2]. Little improve-
ment has been made for the patients’ long-term survival though
certain advances have been made in chemotherapeutics in recent
years [3]. Target therapies such as EGFR (Epidermal Growth Factor
Receptor) inhibitors, MET inhibitors, and mTOR (Mammalian
Target of Rapamycin) inhibitors have been evaluated in clinical
studies/trials but no obvious benefit has been seen [4]. Therefore,
it remains essential and vital to understand the molecular mecha-
nisms of gastric cancer in order to identify new biomarkers and
target for personalised disease management.Bone morphogenetic proteins (BMPs) belong to the transform-
ing growth factor b (TGF-b) superfamily. BMP ligands signal
through transmembrane receptors including BMPR-I (ACVRL1,
ACVR1, BMPR1A, ACVR1B, TGFBR1, BMPR1B, ACVR1C, also known
as ALK1-7) and BMPRII (TGFBR2, TGFBR3, BMPR2, ANCR2A and
ANCR2B) to induce differentiation of mesenchymal cells and form
cartilage and bone tissue. BMPs are essential and indispensable for
development of diverse tissues and organs such as bone, cartilage,
heart and other organs. It has been shown that BMPs are involved
in the development of many tumours. There are two pathways
mediating signalling for BMPs: Smad-dependent pathway and
Smad-independent pathways [5]. Upon binding to pre-formed
BMP receptors complex which comprises both Type 1 and Type 2
receptors, activated BMPR-II phosphorylates the GS region of
BMPR-I leading to activation and translocation of R-Smads into
nucleus and regulation of BMP responsive genes [6]. Upon binding
to the BMP ligands [7], the Type 1 receptor recruits Type 2 receptor
178 Z. Sun et al. / Computational and Structural Biotechnology Journal 18 (2020) 177–188which form BMP-induced receptor complex. The Type I receptor
then activates MAPK pathway via an adaptor protein, XIAP [8].
Aberrant expression of BMPs has been shown in a number of
solid tumours, including bone tumours, odontogenic tumours,
and maxillofacial tumours [9–13], and they are also related to
the development and metastasis of tumours [14–17]. For example,
overexpression of BMP6 in prostate cancer is associated with
skeletal metastasis [14]. It has been shown that BMP4 promotes
the migration and invasion of breast cancer cells through an up-
regulation of MMP1 and CXCR4 [15]. In contrast to these positive
effects in the disease progression, certain BMPs exhibit inhibitory
effects on tumour cells. For example, BMP10 inhibits the -
growth of prostate cancer cells largely due to induced apoptosis
via Smad-independent signalling in which XIAP and ERK1/2 are
involved. It can also suppress migration and invasion of prostate -
cancer cells [16].
To date, the role played by BMPs in gastric cancer remains lar-
gely unknown. An increased expression of BMP4 has been shown
in gastric adenocarcinomas in comparison with normal gastric
mucosae which is inversely related to the prevalence of lymph
node metastasis and tumour invasiveness [18]. BMP2 was more
frequently observed in intestinal-type cases than diffuse-type
cases in gastric cancers which is associated with the status of dif-
ferentiation and lymph node metastasis [19]. BMP2 promotes
metastases in gastric cancer through regulation of NF-jB and
MMP9 activity via PI3K/Akt and MAPK pathways [19].
In the current study, we aim to evaluate the role played by
BMPs (with a focus on BMP2 to BMP7) and BMP receptors in gastric
cancer by analysing gene array data and RNA sequencing data of
gastric cancers.2. Materials and methods
2.1. Database and online analysis
Download the RNA sequencing data in the Stomach adenocarci-
noma (STAD) dataset of The Cancer Genome Atlas (TCGA). The nor-
malised gene expression level of the dataset was analysed to
evaluate the expression of BMPs and BMP receptors in gastric can-
cer tissues (n = 274) compared to normal gastric tissues (n = 33).
The gene expression profiles (GSE33335 and GSE27342) were
downloaded from the Gene Expression Omnibus database and nor-
malized using Limma package in R software. We verified the above
results in GSE33335 (n = 50, GPL5175) and GSE27342 database
(n = 160, GPL5175), which comprise 25 and 80 pairs of tumours
and corresponding adjacent normal gastric tissues, respectively.
To evaluate the association with prognosis, we performed sur-
vival analyses for the BMPs (BMP2-7) and BMP receptors in
TCGA-STAD (n = 375) using the LinkedOmics [20]. The Kaplan
Meier plotter (http://kmplot.com/), which is based on an online
database and is capable of assessing the association of genes on
survival in four types of cancer samples including breast cancer,
ovarian cancer, lung cancer and gastric cancer, was also performed
to evaluate the association of BMPs and BMP receptors with prog-
nosis of GC patients (n = 1065) [21]. Auto-selected cut-off values
were employed.
After identifying the genes with significantly altered expression
levels in gastric cancer tissues and the genes associated with prog-
nosis of gastric cancer patients, we focussed our investigation on
the genes which fell into both of these categories.
TCGA-STAD (treated as discovery cohort) and GSE 84433 data-
base (n = 357, employed for validation) were analysed to evaluate
the correlation between BMPs/BMP receptors and key genes rele-
vant to the hallmarks of cancer including proliferation, cell cycle,
invasion, epithelial mesenchymal transition (EMT), stemness,angiogenesis and lymphangiogenesis. The results were presented
with heatmaps and scatter plots.
Overall correlation between BMPs/BMPR mRNA expression and
some hallmarks of cancer (TCGA-STAD) was plotted using Circos
(available from http://qplot.cn/) [22].
2.2. Statistical analysis
Following a normality check, t-tests were employed for nor-
mally distributed data whilst non-normally distributed data was
analysed using Mann-Whitney tests. The Spearman test was used
to analyse the correlation between different genes. Association
with patients’ survival was evaluated using Kaplan-Meier survival
analysis. Differences were considered to be statistically significant
at p < 0.05.3. Results
3.1. Aberrant expression of BMPs and receptors in human gastric
cancer tissues
Expression of the BMPs (BMP2-7) in GC was first analysed using
the RNA sequencing data of the TCGA-STAD cohort. BMP2, BMP4
and BMP6 are expressed at relatively higher levels, while the
expression levels of BMP3 and BMP5 were relatively lower among
the BMPs (Fig. 1A). The expression of these BMPs was then evalu-
ated against their expression in normal gastric tissues. The expres-
sion of BMP4 in gastric cancer tissues was significantly increased
compared with normal tissue, while the expression of BMP3 and
BMP5 were significantly decreased (Fig. 1B) (Supplementary
Table 1). The reduced expression of BMP5 in gastric cancer was
also evident in both GSE33335 (Fig. 1C) (n = 50, GPL5175) and
GSE27342 database (n = 160, GPL5175), which comprises 25 and
80 tumours paired with adjacent normal tissues, respectively (Sup-
plementary Table 2).
The expression of BMP receptors in GC was also evaluated.
TGFBR2, ACVR1B, ACVR1, BMPR2, and TGFBR1are expressed at
higher levels compared with BMPR1B and BMPR1B (Fig. 1D). In
comparison to the expression in normal gastric tissues, ACVRL1,
ACVR1, ACVR1B, TGFBR1 and BMPR2 exhibit increased expression
in the gastric cancers, while the expression of TGFBR3 was signifi-
cantly reduced in GC (Fig. 1E) (Supplementary Table 1). The
increased expression of ACVRL1, ACVR1, TGFBR1 and BMPR2 were
also evident in both GSE33335 (Fig. 1F) (n = 50, GPL5175) and
GSE27342 database (n = 160, GPL5175) (Supplementary Table 2).
3.2. The aberrant expression of BMP/BMP receptors is involved in the
disease progression of GC
The correlation between the expression BMP/BMPRs and clinic
pathological parameters was analysed in the TCGA-STAD cohort.
Certain BMPs and BMP receptors were significantly correlated with
the T stage of GCs including BMP4, BMP6, ACVRL1 (ACVRL1),
ACVR1, TGFBR1, BMPR1B, TGFBR2, TGFBR3 and BMPR2 (Fig. 2A).
In addition, elevated expression of ACVR1, TGFBR1, TGFBR2 and
BMPR2 was associated with lymph node metastases (Fig. 2B). No
obvious change was seen in the expression of these BMPs and
BMP receptors when the gastric tumours developed distant metas-
tases (data not shown).
We further evaluated the prognostic value of BMPs and BMPRs
in GC using TCGA-STAD dataset and an online analysis tool Linke-
dOmics. Higher expression of BMP3, ACVR1, TGFBR1, BMPR1B,
TGFBR2 and BMPR2 in the primary tumours are associated poorer
overall survival (Table 1 and Supplementary Fig. 1). This is further
supported by the Kaplan-Meier analyses using the KMplot. Patients
Fig. 1. Aberrant expression of BMPs and BMP receptors in gastric cancer. (A) Expression of BMPs in gastric tumour tissues was analysed using the TCGA database (n = 274,
TCGA-STAD cohort). (B) Expression of BMP5 in gastric tumour tissues (n = 274) compared with normal tissues (n = 33) at mRNA levels in the TCGA database. (C) The mRNA
expression of BMP5 in gastric tumours and paired adjacent normal gastric tissues (n = 50, GSE33335). (D) Expression of BMP receptors was analysed in the TCGA-STAD cohort
(n = 274). (E) Expression of ACVRL1, ACVR1, TGFBR1 and BMPR2 in gastric tumour tissues (n = 274) compared with normal tissues (n = 33) in the TCGA-STAD. (F) The mRNA
expression of ACVRL1, ACVR1, TGFBR1 and BMPR2 in the gastric tumours in comparison with paired adjacent normal gastric tissues (n = 50, GSE33335).
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sion of BMP3, ACVR1, TGFBR1, BMPR1B, TGFBR2 and BMPR2
(Fig. 2C).
3.3. BMP and tumour growth in GC
To explore the molecular machinery underlying the implication
of BMP/BMPRs in disease progression of GC, correlation between
BMP/BMPR and cell proliferation index MKI67 and PCNA was
determined. An inverse correlation was frequently seen for mostof the BMPs and BMP receptors we examined (Fig. 3A and Supple-
mentary Fig. 2A), BMP3, BMP5, ACVRL1, TGFBR1, TGFBR2 and
TGFBR3 exhibited significant inverse correlation with both MKI67
and PNCA in the gastric tumours (Fig. 3B and Supplementary
Fig. 2B). In line with the inverse correlation between the expres-
sion of BMP/BMPRs and proliferation markers, correlations were
also present for cell cycle regulators in the gastric tumours. Certain
BMPs and BMPRs were inversely correlated with cell cycle promot-
ing factors such as CCNA2, CCNB1, CCNB2, CCNE2, CDK1 and CDK3,
while a positive correlation was evident for cell cycle inhibitors
Fig. 2. Aberrant expression of BMPs and BMP receptors correlates with the disease progression and prognosis of gastric cancer. (A) Correlation between BMPs/BMPRs mRNA
expression and T stage, N stage of gastric cancer in the TCGA cohort (n = 274). (B) Kaplan-Meier survival analyses showed correlations between BMPs/BMPRs expression and
overall survival of GC patients (n = 876) using the online Kaplan-Meier survival analysis (http://kmplot.com).
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TGFBR1, BMPR1B, TGFBR2, TGFBR3 and BMPR2 (Fig. 4B). These
were also observed in the GSE84433 cohort (data not shown).3.4. BMP and regulators of invasion/migration in GC
Poor differentiation, stemness and invasiveness are hallmarks
of cancer cells. We analysed the correlation between the expres-
sion of BMP/BMPRs and some important molecules includingEMT related molecules (SNAI1, SNAI2, and TWIST1), matrix metal-
loproteinases (MMP2, MMP7, MMP9 and MMP14) and stemness
markers (CD34, CD44 and CD133). ACVRL1, ACVR1, TGFBR1,
BMPR1B, TGFBR2, TGFBR3 and BMPR2 were positively correlated
with the MMPs (MMP2, MMP7 and MMP14) (Fig. 5), EMT markers
(Fig. 6A and B), and stem cell markers (Fig. 6C and D). The positive
correlation between these molecules and EMT-related molecules,
MMPs and stem cell markers were also observed in the
GSE84433 (data not shown).
Table 1
BMPs/BMPRs expression and overall survival of GC patients (the KMplot cohort).
Gene Median Cut off Median OS (months) p
Low expression (n, %) High expression (n, %)
BMP2 644 429 26 (257, 29.3%) 29.4 (619, 70.7%) 0.055
BMP3 17 23 42.07 (476, 54.3%) 23.9 (400, 45.7%) <0.001
BMP4 111 201 34.1 (605, 69.1%) 22.5 (271, 30.9%) <0.001
BMP5 28 56 29.8 (648, 74.0%) 22.83 (228, 26.0%) <0.01
BMP6 122 88 70.2 (285, 32.5%) 25.9 (591, 67.5%) <0.001
BMP7 116 157 39.8 (534, 61.0%) 2.3 (342, 39.0%) <0.001
ACVRL1 111 127 30.4 (527, 60.2%) 27.47 (349, 39.8%) 0.099
ACVR1 1178 1038 25.17 (313, 35.7%) 31.33 (563, 64.3%) 0.059
BMPR1A 404 394 25.9 (420, 47.9%) 34.1 (456, 52.1%) 0.065
ACVR1B 259 365 30.7 (625, 71.3%) 26.7 (251, 28.7%) <0.05
TGFBR1 70 101 35.77 (556, 63.5%) 23.6 (320, 36.5%) <0.001
BMPR1B 18 7 70.2 (238, 27.2%) 26.7 (638, 72.8%) <0.001
ACVR1C 160 80 45 (419, 66.4%) 57.13 (212, 33.6%) 0.104
TGFBR2 59 47 33.27 (353, 40.3%) 27.4 (523, 59.7%) <0.05
TGFBR3 471 440 32.6 (403, 46.0%) 27.47 (473, 54.0%) <0.05
BMPR2 155 143 47.7 (389, 44.4%) 23.4 (487, 55.6%) <0.001
ACVR2A 406 427 35.77 (489, 55.8%) 25.2 (387, 44.2%) <0.01
ACVR2B 22 30 63.9 (387, 61.3%) 32.1 (244, 38.7%) <0.05
Fig. 3. BMPs/BMPR and tumour growth in GC. Correlation between BMPs/BMPRs mRNA expression and PCNA were analysed using Spearman tests, results shown as a
heatmap (A) and scatter plots (B). BMPs/BMPRs are highlighted with red boxes when they exhibit significantly correlation and are labelled with corresponding correlation co-
efficient. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 4. Correlation between BMPs/BMPRs mRNA expression and cell cycle regulators were shown as heatmap (C) and scatter plots (D). BMPs/BMPRs are highlighted with red
boxes when they exhibit significantly correlation and are labelled with corresponding correlation co-efficient. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
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Angiogenesis is associated with disease progression and prog-
nosis of tumours in the digestive system including colorectal can-
cers [23], gastric cancers [24], oesophageal cancers [25], and
pancreatic cancers [26,27]. In the correlation analyses between
the expression levels of BMP/BMPR and angiogenesis-related fac-
tors, it has been revealed that ACVRL1, ACVR1, TGFBR1, BMPR1B,
TGFBR2, TGFBR3 BMPR2 and BMP3 are positively correlated with
angiogenic markers in both the discovery cohort (TCGA-STAD)
and the validation cohort (GSE84433) (Fig. 7A and B). Clinical
implication was then analysed for overall expression of the top 8
correlated BMPs/BMP receptors including BMPR2, TGFBR2,
ACVRL1, TGFBR3, BMPR1A, ACVR1, BMPR1B and BMP3. A signifi-
cant association with T staging was seen in the TCGA-STAD cohort
but not in the validation cohort (GSE84433) (Fig. 7C). No difference
was observed for the overall expression in tumours regarding their
lymph node metastasis and distant metastases (Fig. 7D). Kaplan-
Meier survival analyses showed that higher levels of the overall
expression were significantly associated with poorer overall sur-
vival in both cohorts (Fig. 7F).
3.6. BMP and lymphangiogenesis/lymph node metastasis in GC
Lymphangiogenesis plays an important role in cancer metasta-
sis, especially for dissemination of cancer cells through lymphaticvessels [28]. Therefore, we analysed the correlation between the
BMP/BMPRs and lymphangiogenesis factors in both TCGA-STAD
and GSE84433 cohorts (Fig. 8A). ACVRL1, TGFBR2, TGFBR3, BMPR2,
TGFBR1, ACVR1, BMP6 and BMP4 present positive correlation with
most of the lymphangiogenesis factors in both discovery and vali-
dation cohorts (Fig. 8B). Overall expression of the top 5 (ACVRL1,
TGFBR2, TGFBR3, BMPR2 and TGFBR1) identified from both cohorts
exhibited significant correlation with lymph node metastasis in
both TCGA and GSE84433 cohorts (Fig. 8C) and also the T stage
of tumours in the TCGA cohort, but not for the T stage in the
GSE84433 cohort and distant metastasis (Fig. 8D). The overall
expression of these five BMP receptors had no association with
overall survival of patients in both TCGA and GSE84433 cohorts
(Fig. 8F).
4. Discussion
BMPs play a vital role in embryo formation, development and
differentiation. Dysregulated BMP pathways may lead to embry-
onic death or abnormalities of tissues and organs including bone,
cartilage, heart and lung [29]. In recent years, more and more stud-
ies have shown that BMPs are also involved in the development
and progression of many kinds of solid tumours [14–17], particu-
larly in the disease-specific bone metastasis. Many studies suggest
that BMPs are involved in the bone metastasis of breast cancer.
Decreased expression of BMP-7 has been indicated in primary
Fig. 5. Correlation between BMPs/BMPRs mRNA expression and MMPs are shown as a heatmap (A) and scatter plots for BMP/BMP receptors with significant correlation (D.
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growth of breast cancer tumours at primary sites and in bone
in vivo [30]. In addition, BMPs are extensively involved in the reg-
ulation of cellular functions of breast cancer cells, including cell
proliferation, apoptosis, migration, invasion, epithelial mesenchy-
mal transition (EMT). BMP-2 and BMP-6 could inhibit the prolifer-
ation of breast cancer cells [31,32]. BMP-2 promotes the
aggressiveness of breast cancer cell (MCF-7), in vitro and in vivo
[33]. In addition, some studies in other tumour types have also
shown that BMPs are also associated with tumour associated
angiogenesis. Current knowledge regarding the role of BMPs on
angiogenesis is mainly from studies in prostate cancer. Experimen-
tal studies showed that BMPs promoted angiogenesis directly and
indirectly through upregulation of the expression of VEGF in osteo-
blasts [34,35].
To date, little is known about the role played by BMPs in gastric
cancer. Recent bioinformatical analyses focused on the discovery of
novel biomarkers/ therapeutic targets, such as the analysis of an
integrated datasets of gastric cancer by the online platform of
KMplot which highlighted 29 markers for poor prognosis of the
disease [21]. The present study was an attempt to dissect the
implication of certain BMPs in gastric cancer by analysing publicly
available data in a relatively comprehensive fashion but more
specifically focusing on the BMPs and corresponding molecular
machineries instead of examining the whole transcriptome. We
analysed the expression of BMPs (BMP2-7) and their receptors in
gastric cancer using the TCGA gastric cancer database, and a fur-
ther validation was performed in two GEO databases (GSE33335
and GSE27342) which have both gastric tumours and paired adja-
cent normal tissues. After the verification, it was found that the
expression level of BMP5 in gastric cancer tissues was significantly
decreased compared with normal tissues, while the expression
levels of ACVRL1, ACVR1, TGFBR1 and BMPR2 were significantly
increased. BMPR2 mediates inhibitory effect on cell proliferation.
Reduced expression of BMPR2 has been evident in some solidtumours, such as prostate cancer, breast cancer and bladder cancer
[36]. We also analysed the expression of these five molecules in
other tumours, especially other digestive tract tumours (oe-
sophageal cancer, colon cancer, rectal cancer, pancreatic cancer,
liver cancer, cholangiocarcinoma) using the TCGA database. The
expression of these genes in oesophageal cancer, liver cancer and
cholangiocarcinoma appeared to be similar as that was seen in gas-
tric cancer, but not in pancreatic cancer. In pancreatic cancer, the
expression level of BMP5 is higher than that in normal tissues,
while the expression of ACVRL1, TGFBR1 and BMPR2 are reduced
(data not shown). We speculate that the role played by BMP5,
ACVRL1, ACVR1, TGFBR1, and BMPR2 in gastric cancer, oesopha-
geal cancer, and hepatobiliary carcinoma may be different from
those in pancreatic cancer.
It has been well-demonstrated that most BMPs elicit inhibitory
effect on the growth of non-transformed epithelial, endothelial and
haematopoietic cells, and also primary fibroblasts of embryonic
origin [37]. The inhibition of growth was often executed by BMP/
BMPR/Smad induced cell-cycle inhibitors CDKN2B, CDKN1A and
CDKN1C leading to an arrest at G1 phase [38]. BMPs could regulate
the proliferation of breast cancer cells in some studies, and the nat-
ure of cell response is influenced by the individual BMP, with some
BMPs having an inhibitory effect on proliferation of breast cancer
cells, while others show a reverse effect. For example, BMP-2 inhi-
bits the proliferation of breast cancer cells via up-regulation of
cyclin kinase inhibitor CDKN1A [39], but BMP-4 has a synergetic
effect on the proliferation of breast cancer cells induced by fibrob-
last growth factor (FGF), epidermal growth factor (EGF) and hepa-
tocyte growth factor (HGF) [40]. At present, only a few studies have
explored the relationship between BMP/BMPR and proliferation of
gastric cancer cells. For example, several studies showed that
BMP2 could inhibit the growth of gastric cancer cells through
CDKN1A/WAF1/CIP1 [41–43]. BMP2 and BMP4 may function as
potent tumour suppressors in diffuse-type gastric carcinoma, and
the inhibitory effect of BMP-4 on the growth is mediated in part
Fig. 6. Aberrant expression of BMPs/BMPR correlates with the EMT and stemness in GC. Shown are correlations between BMPs/BMPRs mRNA expression and EMT markers as
heatmap (A) and scatter plots (B). Correlation between BMPs/BMPRs mRNA expression and stem cell markers are shown as heatmap (C) and scatter plots (D).
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most of BMP/BMPRs were negatively correlated with cell prolifer-
ation related marker PCNA and MKI67, especially for BMP3,
ACVRL1, TGFBR1, BMPR1B, TGFBR2, TGFBR3 and BMPR2. Further-
more, they were also significantly and negatively correlated with
cell cycle promoting factors such as CCNA2, CCNB1, CCNB2, CCNE2,
CDK1 and CDK3, while positively correlated with cell cycle inhibi-
tors such as CDKN2B and CDKN1C. This suggests that BMP3,
ACVRL1, TGFBR1, BMPR1B, TGFBR2, TGFBR3 and BMPR2 act as
inhibitory factors for the proliferation of gastric cancer by a regu-
lation of the cell cycle.
Invasiveness is the essential characteristic for cancer cells to
spread. The possible role of BMPs in the regulation of cancer cell
invasiveness remains unclear. Previous studies showed that
BMP2 and BMP7 may promote the invasion and migration of gas-
tric cancer cells via the induction of tenascin-W in the tumour sur-
rounding stroma. [33,45,46], However, some BMPs have been
reported to inhibit the aggressiveness of breast cancer cells [47].
MMPs are indispensable for cancer cells during their local invasion
and distant metastasis. To date, little is known about the potential
of BMP signalling in the regulation of MMPs which has just beenhighlighted by the current study. BMP2 has been shown to sup-
press the expression of MMP13 in breast cancer cells [48]. The pre-
sent study revealed BMP receptors including ACVRL1, ACVR1,
TGFBR1, BMPR1B and TGFBR2 are positively correlated with the
expression MMP2, MMP7 and MMP14.
In addition to the positive correlation between BMP receptors
and MMPs, we also analysed the correlation between the BMP/
BMPRs and EMT in GC. EMT is also very important during the
development and progression of cancer. It not only causes a dis-
ruption of epithelial homeostasis which may lead to carcinogene-
sis, it can also transform the indolent tumour cells into a more
aggressive colony, leading to metastasis. BMP-4 can subvert the
ability of mammary epithelial cells to form polarized lumen-
containing structures and also endows them with invasive proper-
ties [49]. BMP-7 has been shown to induce EMT with classical
changes in morphology and promote both motility and invasive-
ness in prostate cancer cells [50]. In contrast, some BMPs are able
to reverse EMT and reduce the aggressive properties of tumour
cells. For example, BMP-6 restores E-cadherin-mediated cell-to-
cell adhesion and prevents breast cancer metastasis through the
downregulation of ẟEF1 [51]. It was not a surprise that a positive
Fig. 7. Association between BMPs/BMPRs and angiogenesis in GC. (A) Correlations between BMPs/BMPRs mRNA expression and angiogenesis markers in both TCGA-STAD
(cohort for discovery) and GSE84433 (cohort for validation) cohorts are shown as heatmaps. (B) Shown are the overlapping BMPs/BMPRs that are more closely associated
with angiogenic markers in both GC cohorts. (C) Correlation between overall expression (BMPR2, TGFBR2 and ACVRL1) and T stage, N stage, M stage and prognosis of gastric
cancer were analysed in both TCGA-STAD and GSE84433 cohorts. Overall expression was calculated using an equation: overall expression of A/B/C = Log (10^(Expression
value of A))(10^(Expression value of B))(10^(Expression value of C)).
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(also known as slug), TWIST1, VIM, CDH1 and CDH2) and BMP
receptors as they are induced by the BMP/Smad signalling.
Tumour stem cells are a group of tumour cells with self-renewal
ability and multi-directional potential regarding differentiation.
They play a key role in the occurrence, development, invasion
and metastasis of tumours. Some recent studies suggested that
cancer stem cells might form the basis of cancer metastasis[34,52]. The current analyses showed a markedly positive correla-
tion between CD34 and two BMP receptors (ACVRL1 and TGFBR2)
in GC though this may also have implications in tumour associated
angiogenesis. Taken together, it was shown that ACVRL1, ACVR1,
TGFBR1, BMPR1B, TGFBR2, TGFBR3 and BMPR2 were all significant
positively with EMT markers, MMPs and stem cell markers. It sug-
gests that these molecules may contribute to the enhanced inva-
siveness of gastric cancer cells leading to spread and metastasis.
Fig. 8. BMPs/BMPR and lymphangiogenesis/lymphatic metastasis in GC. (A) Shown are heatmaps of correlations between BMPs/BMPRs mRNA expression and
lymphangiogenesis markers in both TCGA-STAD and GSE84433 cohorts for discovery and validation. (B) Shown are BMPs/BMPRs highly associated lymphangiogenesis
that are most commonly seen in both GC cohorts. (C) Correlation between overall expression (ACVRL1, TGFBR2, TGFBR3, BMPR2 and TGFBR1) and T stage, N stage, M stage
and prognosis of gastric cancer were analysed in both TCGA-STAD and GSE84433 cohorts. The overall expression was calculated following the same formula shown in the
Fig. 5.
186 Z. Sun et al. / Computational and Structural Biotechnology Journal 18 (2020) 177–188Angiogenesis is an important event during the development
and progression of tumours. Current knowledge regarding the
role of BMPs and angiogenesis is mainly from studies in prostate
cancer. It has been demonstrated that BMPs, including BMP2, 4, 6,
7 and GDF5 can induce angiogenesis through upregulation of
VEGF in prostate cancer [34]. In this study, most of the BMP/
BMPRs are significantly positively correlated with angiogenesis
markers, especially for BMPR2, TGFBR2, ACVRL1, TGFBR3,BMPR1A, ACVR1, BMPR1B, BMP3, and the higher expression of
ACVRL1, ACVR1, BMPR1B, TGFBR2, TGFBR3, BMPR2 were indeed
significantly correlated with higher T stage of GC. It suggests that
BMP signalling plays a profound role in the tumour growth and
expansion through their regulation of tumour associated angio-
genesis. Therapeutic potential of targeting BMP receptors to pre-
vent tumour associated angiogenesis in GC warrants further
investigation.
Fig. 9. Overall correlation between BMPs/BMPR mRNA expression and some hallmarks of cancer (TCGA-STAD) was plotted using Circos (available from http://qplot.cn/) [22].
The three highly associated BMPs, type 1 receptors and type receptors are highlighted, respectively. Results shown are from the analyses of gene expression in the TCGA-STAD
cohort using Spearman correlation test.
Z. Sun et al. / Computational and Structural Biotechnology Journal 18 (2020) 177–188 187Lymph node metastasis is of great significance for the staging
and prognosis of many tumours, and lymphangiogenesis is a nec-
essary condition for lymph node metastasis. However, current
knowledge about the role of BMP/BMPR in lymphangiogenesis
remains poor. BMP9 has been shown to inhibit lymphatic vessel
formation via ACVRL1 during development and cancer progression
[53]. In the current study, we found that there were marked and
positive correlations between BMP/BMPRs and lymphangiogenesis
factors, especially for ACVRL1, TGFBR2, TGFBR3, BMPR2, TGFBR1,
ACVR1, BMP6 and BMP4. Furthermore, higher expression of
ACVR1, TGFBR1, TGFBR2, and BMPR2 were indeed significantly
correlated with lymphatic metastases in GC.
Furthermore, a retrospective study analysed 2000 GC patients
in 22 Italian hospitals diagnosed over a period from 1998 to
2011. 208 (10%) had bone metastases, either presented at the diag-
nosis of GC (59/208) or developed the metastases after the diagno-
sis (149/208) [54]. Osteolytic lesions (52%) appeared to be more
common than the osteoblastic lesions (23%) and mixed ones
(25%). The implications in bone metastasis could not be analysed
due to lack of relevant information in the data of the present study.
However, this highlights a potential area of future study.5. Conclusion
The study showed that the expression level of BMP5 in gastric
cancer tissues was significantly lower than the levels found in nor-
mal tissues, and the expression levels of ACVRL1, ACVR1, TGFBR1,and BMPR2 were significantly increased. In addition, the survival
analysis in TCGA and GEO databases showed that patients with
higher expression of BMP3, ACVR1, TGFBR1, BMPR1B, TGFBR2
and BMPR2 had much shorter survival times than the patients with
low expression tumours. These results are important for the diag-
nosis and prognosis assessment of gastric cancer patients. Further
analyses showed that BMP/BMPR may elicit inhibitory an effect on
proliferation in gastric tumours but promote gastric cancer inva-
sion as they exhibit a positive correlation with certain MMPs,
EMT markers and stemness markers. BMP/BMPR also has a signif-
icant positive correlation with angiogenesis and lymphangiogene-
sis, mainly concentrated in BMP3, ACVRL1, TGFBR1, BMPR1B,
TGFBR2, TGFBR3 and BMPR2 (Fig. 9). Further in vivo and in vitro
investigations will shed light on their multiple roles in the
tumourigenesis and disease progression of GC, and also their diag-
nostic, prognostic and therapeutic potential.Declaration of Competing Interest
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